HomeNewsBusinessDiageo exits HipBar investment, says alcohol home delivery model will take years to mature
Trending Topics

Diageo exits HipBar investment, says alcohol home delivery model will take years to mature

HipBar co-founder Natarajan said that the firm faced some pushback from some pockets of the trade and the state excise department of Karnataka and this matter is still sub-judice.

July 26, 2021 / 11:24 IST
Story continues below Advertisement
The move comes at a time when more and more states are joining the alcohol home delivery bandwagon. Representative image
The move comes at a time when more and more states are joining the alcohol home delivery bandwagon. Representative image

Diageo has exited from its investment in alcohol home delivery startup HipBar. Diageo invested Rs 27 crore via domestic entity USL in exchange for the stake in the Chennai-based company in 2018.

The UK-based liquor company crore sold its 26 percent stake in HipBar to the startup’s promoter Prasanna Natarajan for Rs 52 lakh, Times of India reported.

Story continues below Advertisement

The move comes at a time when more and more states are joining the alcohol home delivery bandwagon.

Stating the reason behind the decision, Diageo spokesperson said that, while home delivery had opened up in several states since 2020, it would take some years to mature as a model."

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show